ProfileGDS5678 / 1429045_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 88% 86% 86% 86% 87% 90% 88% 88% 87% 88% 89% 88% 88% 88% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.8148988
GSM967853U87-EV human glioblastoma xenograft - Control 26.5612186
GSM967854U87-EV human glioblastoma xenograft - Control 36.6167486
GSM967855U87-EV human glioblastoma xenograft - Control 46.7781186
GSM967856U87-EV human glioblastoma xenograft - Control 56.8140387
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.9029490
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.7279988
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.7768888
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.604787
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.8790988
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.9165289
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.8847688
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.8170888
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.7808388